Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Gritstone Bio

Evaluate

April 16, 2023

AACR 2023 – more hope for Moderna’s neoantigen immunotherapy

After Moderna/Merck & Co’s December splash, full data from Keynote-942 stand up to scrutiny.

Thumbnail
December 13, 2022

Moderna gets some skin in the cancer vaccine game

Article image
Vantage logo
December 09, 2022

Not so fast for some accelerated approvals

The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.

Article image
Vantage logo
October 14, 2022

Cancer “vaccines” enter the neoantigen stage

Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.

Article image
Vantage logo
September 14, 2022

Esmo 2022 movers – Kras backfires

Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.

Article image
Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

But progress – or lack thereof – with lenacapavir is a more immediate concern.

Article image
Vantage logo
June 30, 2021

Altimmune looks to obesity as Covid-19 vaccine crashes

Article image
Vantage logo
June 03, 2021

Biopharma and venture capital: a deep dive

Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.

Article image
Vantage logo
May 06, 2021

More evidence backs Covid-19 shots against variants

Article image
Vantage logo
February 25, 2021

Vaccine developers move to stay ahead of Covid-19 variants

Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.

Article image
Vantage logo
February 19, 2021

Immunome soars 76% on Covid-19 hopes – but that's nothing

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up